Stocks and Investing
Stocks and Investing
Thu, December 17, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, December 16, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vamil Divan Initiated (ACAD) at Strong Buy and Held Target at $69 on, Dec 16th, 2020
Vamil Divan of Mizuho, Initiated "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy and Held Target at $69 on, Dec 16th, 2020.
Vamil has made no other calls on ACAD in the last 4 months.
There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Vamil's Rating of Hold.
This is the rating of the analyst that currently disagrees with Vamil
- Danielle Brill of "Raymond James" Upgraded from Buy to Strong Buy and Held Target at $65 on, Monday, November 16th, 2020
Contributing Sources